Search clinical trials for: [11C] JNJ-42491293

Total 3248 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of [11C]JNJ-42491293, a Possible PET Ligand for the mGlu2 Receptor, in Healthy Adult Volunteers

Healthy
Hoffmann-La Roche

Completed

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Johnson & Johnson Vision Care, Inc.

Completed

Evaluating Soft Contact Lens Prototypes for Myopia Control

Visual Acuity

China
Janssen Cilag N.V./S.A.

Completed

Study to Assess the Absorption, Metabolism and Excretion of 14C-JNJ-63623872 After a Single Dose in Healthy Male Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of Brain Drug Transporters Using P-glycoprotein and Breast Cancer Resistance Protein Substrates and by Using the Positron Emission Tomography Ligand 11C-JNJ-63779586 in the Human Brain

Alzheimer Disease

Belgium
Wendell Yap, MD
University of Kansas Medical Center

No longer available

Clinical Management Decisions for Recurrent Prostate Cancer Patients Based on [11C]Acetate PET Scan

Prostate Cancer

United States
National Institute of Mental Health (NIMH)

Completed

Positron Emission Tomography Imaging of Dopamine Receptors Using the Tracer [11C]NNC-112

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate the Absorption, Metabolism, and Excretion of Canagliflozin (JNJ-28431754) in Healthy Male Volunteers

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of (14C) Radiolabeled JNJ-56136379 in Healthy Male Participants

Healthy

United States
Janssen Cilag N.V./S.A.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of JNJ-38877618 in Healthy Male Participants

Healthy Volunteers

United Kingdom
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
Janssen Research & Development, LLC

Completed

A Study to Investigate the Absorption, Distribution, Metabolism, and Excretion of 14C-JNJ-42847922 After a Single Oral Dose of 40 mg in Healthy Subjects

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Evaluate of the Absorption, Metabolism, and Excretion of 14C-JNJ-39823277 in Healthy Male Participants

Healthy

Belgium
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
MetiMedi Pharmaceuticals

Unknown

OMT-111 for Terminal Stage Solid Tumors

Breast Cancer | Pancreatic Cancer | Lung Cancer

Vietnam
Emory University

Completed

Norepinephrine Transporter Availability in PTSD

Posttraumatic Stress Disorder

United States
University of North Carolina, Chapel Hill
Boston Children's Hospital; Medical College of Wisconsin; National Football League

Enrolling by invitation

NFL LONG Prospective Study

Concussion, Brain

United States
Weill Medical College of Cornell University

Completed

Carbon-11 Butanol: Whole Body Radiochemical and Radiation Safety ([11C]Butanol)

Neuro-Degenerative Disease

United States
Columbia University

Recruiting

Exploratory Evaluation of [11C]MPC6827

Neurodegenerative Diseases | Amyotrophic Lateral Sclerosis | Alzheimer Disease

United States
National Institute of Mental Health (NIMH)

Terminated

PET Imaging of Neuroinflammation in Neurodegenerative Diseases Via a Novel TSPO Radioligand

Dementia

United States
Janssen Research & Development, LLC

Recruiting

A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer

Lymphoma, Non-Hodgkin

Denmark, Israel, Spain, Australia
Janssen-Cilag International NV

Completed

A Study to Investigate the Pharmacokinetics of JNJ-42396302, JNJ-53773187 and JNJ-42692507 in Healthy Male Participants

Healthy
Janssen Research & Development, LLC

Completed

Study to Assess the Relative Bioavailability of Orally Administered JNJ-42756493 Tablet Versus JNJ-42756493 Capsule in Healthy Participants

Healthy

Belgium
Columbia University

Completed

Imaging Inflammation in Alzheimer's Disease With 11C-ER176

Alzheimer Disease

United States
Avid Radiopharmaceuticals
General Electric; American College of Radiology Imaging Network

Completed

Ability Of ([18F]-AV-45) PET Scan to Distinguish Alzheimer's Disease Subjects From Cognitively Normal Individuals

Alzheimer's Disease

United States
Janssen Research & Development, LLC

Completed

A Study to Assess Interaction Between JNJ-64417184 and JNJ-53718678 After Single and Multiple Dosing in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Completed

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-55375515 in Healthy Male Participants

Healthy

Netherlands
Hoffmann-La Roche

Completed

A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)

Solid Tumors

Hungary
Hoffmann-La Roche

Completed

Evaluation of [11C]RO6924963, [11C]RO6931643, and [18F]RO6958948 as Tracers for Positron Emission Tomography (PET) Imaging of Tau in Healthy and Alzheimer's Disease (AD) Participants

Alzheimer's Disease, Healthy Volunteer

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JNJ-54861911 in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-64991524 in Healthy Participants

Healthy

Belgium
St. Jude Children's Research Hospital

Available

Expanded Access [11C] Methionine PET Imaging

Head and Neck Neoplasms | Central Nervous System Tumor

United States
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Yale University
National Center for Complementary and Integrative Health (NCCIH)

Recruiting

Novel in Vivo Synaptic Imaging in Experienced Meditators (app311_med)

Behavior, Health

United States
Janssen Research & Development, LLC

Completed

A Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-54861911 in Healthy Volunteers Compared With Placebo

Healthy

Belgium
Johnson & Johnson Enterprise Innovation Inc.

Recruiting

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

Advanced Solid Tumors

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Single and Multiple Dose Study to Explore the Safety Of JNJ-40346527 In Healthy Volunteers

Health

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Universitaire Ziekenhuizen KU Leuven
CHDI Foundation, Inc.

Completed

Dosimetry of [11C]CHDI-180R and [11C]CHDI-626.

Huntington Disease

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants

Healthy

Belgium
Janssen Pharmaceutical K.K.

Completed

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Lymphoma, Non-Hodgkin | Chronic Lymphocytic Leukemia

United States, Israel, Korea, Republic of, Netherlands, Belgium, Spain, Australia, Poland, France, Georgia, Moldova, Republic of, Ukraine
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Bioavailability, Safety and Tolerability of a Solid Dosage Formulation Relative to a Suspension of JNJ-54175446 in Healthy Male and Female Participants

Healthy

United States
Janssen R&D Ireland

Completed

A Study to Compare the Bioavailability of JNJ-47910382 Formulated as a Tablet and as Suspension in Healthy Participants

Healthy Participants

Belgium
Janssen Research & Development, LLC

Terminated

A Study to Investigate Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-64140284 in Healthy Participants

Healthy

Belgium
Yale University
National Institute of Mental Health (NIMH); National Institutes of Health (NIH)

Recruiting

SV2A & TSPO PET Imaging Measures to Reveal Mechanisms of HIV Neuropathogenesis During Antiretroviral Therapy (ART)

Healthy | HIV Dementia | HIV Associated Neurocognitive Disorder | HIV Encephalitis

United States
Janssen Research & Development, LLC

Recruiting

A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder (SunRISe-4)

Urinary Bladder Neoplasms

United States, Korea, Republic of, France, Israel, Spain, Italy, United Kingdom, Belgium, Germany, Netherlands
Janssen Research & Development, LLC

Terminated

An Extension Study to Evaluate the Long-Term Safety and Tolerability of JNJ-54861911 in Participants in the Early Alzheimer's Disease Spectrum

Alzheimer Disease

France, Spain, Netherlands, Belgium, Germany, Sweden

3

Subscribe